Float Short %

3.4

Margin Of Safety %

-1

Put/Call OI Ratio

1.23

EPS Next Q Diff

0.58

EPS Last/This Y

3.98

EPS This/Next Y

1.34

Price

143.18

Target Price

168.56

Analyst Recom

1.44

Performance Q

21.05

Relative Volume

0.99

Beta

0.32

Ticker: NBIX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	NBIX	134.97	0.79	0.06	15993
2024-12-20	NBIX	135.46	0.78	0.16	16138
2024-12-23	NBIX	137.05	0.83	0.10	7824
2024-12-24	NBIX	140.04	0.82	0.10	7860
2024-12-26	NBIX	139.09	0.83	0.02	7854
2024-12-27	NBIX	139.44	0.82	0.17	7892
2024-12-30	NBIX	137.15	0.82	0.00	7905
2024-12-31	NBIX	136.06	0.83	0.19	7883
2025-01-02	NBIX	137.63	0.82	0.27	7895
2025-01-03	NBIX	138.11	0.81	0.50	7971
2025-01-06	NBIX	137.32	0.81	0.85	7982
2025-01-07	NBIX	137.55	0.83	0.89	12295
2025-01-08	NBIX	138.55	0.85	0.57	15395
2025-01-09	NBIX	138.71	0.85	0.57	15395
2025-01-10	NBIX	140.86	0.85	0.06	15845
2025-01-13	NBIX	142.99	0.83	0.06	16068
2025-01-14	NBIX	139.45	1.28	0.11	13323
2025-01-15	NBIX	142.49	1.30	0.15	13213
2025-01-16	NBIX	142.03	1.28	0.00	13352
2025-01-17	NBIX	143.2	1.23	0.28	13552
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	NBIX	134.91	24.4	463.8	6.54
2024-12-20	NBIX	135.49	24.4	472.3	6.54
2024-12-23	NBIX	136.99	24.2	480.5	6.59
2024-12-24	NBIX	136.53	24.2	464.5	6.54
2024-12-26	NBIX	139.03	24.2	487.8	6.54
2024-12-27	NBIX	139.42	24.2	471.1	6.54
2024-12-30	NBIX	136.99	24.2	449.2	6.54
2024-12-31	NBIX	136.50	24.2	463.7	6.54
2025-01-02	NBIX	137.81	24.2	478.4	6.54
2025-01-03	NBIX	138.11	24.2	470.0	6.54
2025-01-06	NBIX	136.87	24.2	458.5	6.54
2025-01-07	NBIX	137.55	24.2	473.6	6.54
2025-01-08	NBIX	138.71	24.2	477.1	6.54
2025-01-09	NBIX	138.71	24.2	468.1	6.54
2025-01-10	NBIX	140.90	24.2	485.0	6.54
2025-01-13	NBIX	143.04	24.2	504.7	6.54
2025-01-14	NBIX	139.49	24.2	461.2	6.54
2025-01-15	NBIX	142.56	24.2	512.1	6.54
2025-01-16	NBIX	141.88	24.2	483.0	6.54
2025-01-17	NBIX	143.18	25.5	497.9	6.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	NBIX	-3.27	-0.49	3.97
2024-12-20	NBIX	-3.30	-0.49	3.97
2024-12-23	NBIX	-3.29	-0.49	3.97
2024-12-24	NBIX	-3.29	-0.49	3.97
2024-12-26	NBIX	-3.31	-0.49	3.44
2024-12-27	NBIX	-3.30	-0.49	3.44
2024-12-30	NBIX	-3.29	-0.55	3.44
2024-12-31	NBIX	-3.29	-0.55	3.44
2025-01-02	NBIX	-3.32	-0.55	3.44
2025-01-03	NBIX	-2.96	-0.55	3.44
2025-01-06	NBIX	-2.95	-0.04	3.44
2025-01-07	NBIX	-2.95	-0.04	3.44
2025-01-08	NBIX	-2.96	-0.04	3.44
2025-01-09	NBIX	-2.96	-0.04	3.44
2025-01-10	NBIX	-2.96	-0.04	3.44
2025-01-13	NBIX	-2.96	-0.02	3.40
2025-01-14	NBIX	-2.96	-0.02	3.40
2025-01-15	NBIX	-2.96	-0.02	3.40
2025-01-16	NBIX	-2.96	-0.02	3.40
2025-01-17	NBIX	-2.96	-0.02	3.40
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.24

Avg. EPS Est. Current Quarter

1.91

Avg. EPS Est. Next Quarter

1.82

Insider Transactions

-2.96

Institutional Transactions

-0.02

Beta

0.32

Average Sales Estimate Current Quarter

630

Average Sales Estimate Next Quarter

627

Fair Value

141.99

Quality Score

Growth Score

100

Sentiment Score

Actual DrawDown %

9.4

Max Drawdown 5-Year %

-46.4

Target Price

168.56

P/E

38.38

Forward P/E

21.68

PEG

0.65

P/S

6.47

P/B

5.33

P/Free Cash Flow

32.96

EPS

3.73

Average EPS Est. Cur. Y

6.54

EPS Next Y. (Est.)

7.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.21

Relative Volume

0.99

Return on Equity vs Sector %

-4.9

Return on Equity vs Industry %

5.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

497.9

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1700

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y